Mostrar el registro sencillo del ítem
Effects of short- and long-term Mediterranean-based dietary treatment on plasma LC-QTOF/MS metabolic profiling of subjects with metabolic syndrome features: The Metabolic Syndrome Reduction in Navarra (RESMENA) randomized controlled trial
dc.contributor.author | Bondia-Pons I. | |
dc.contributor.author | Martinez J.A. | |
dc.contributor.author | de la Iglesia R. | |
dc.contributor.author | Lopez-Legarrea P. | |
dc.contributor.author | Poutanen K. | |
dc.contributor.author | Hanhineva K. | |
dc.contributor.author | Zulet M.D.L.A. | |
dc.date.accessioned | 2020-09-02T22:13:39Z | |
dc.date.available | 2020-09-02T22:13:39Z | |
dc.date.issued | 2015 | |
dc.identifier | 10.1002/mnfr.201400309 | |
dc.identifier.citation | 59, 4, 711-728 | |
dc.identifier.issn | 16134125 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12728/3826 | |
dc.description | Scope: Adherence to the Mediterranean diet has been associated with a reduced risk of metabolic syndrome (MetS). Metabolomics approach may contribute to identify beneficial associations of metabolic changes affected by Mediterranean diet-based interventions with inflammatory and oxidative-stress markers related to the etiology and development of the MetS. Methods and results: Liquid chromatography coupled to quadrupole-time of flight-MS metabolic profiling was applied to plasma from a 6-month randomized intervention with two sequential periods, a 2-month nutritional-learning intervention period, and a 4-month self-control period, with two energy-restricted diets; the RESMENA diet (based on the Mediterranean dietary pattern) and the Control diet (based on the American Heart Association guidelines), in 72 subjects with a high BMI and at least two features of MetS. The major contributing biomarkers of each sequential period were lipids, mainly phospholipids and lysophospholipids. Dependency network analysis showed a different pattern of associations between metabolic changes and clinical variables after 2 and 6 month of intervention, with a highly interconnected network during the nutritional-learning intervention period of the study. Conclusion: The 2-month RESMENA diet produced significant changes in the plasma metabolic profile of subjects with MetS features. However, at the end of the 6-month study, most of the associations between metabolic and clinical variables disappeared; suggesting that adherence to healthy dietary habits had declined during the self-control period. © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. | |
dc.language.iso | en | |
dc.publisher | Wiley-VCH Verlag | |
dc.subject | Dependency networks | |
dc.subject | LC-QTOF/MS | |
dc.subject | Mediterranean diet | |
dc.subject | Metabolic syndrome | |
dc.subject | Metabolomics | |
dc.subject | biological marker | |
dc.subject | high density lipoprotein cholesterol | |
dc.subject | low density lipoprotein cholesterol | |
dc.subject | triacylglycerol | |
dc.subject | adult | |
dc.subject | blood | |
dc.subject | body mass | |
dc.subject | body weight | |
dc.subject | Caucasian | |
dc.subject | controlled study | |
dc.subject | diet therapy | |
dc.subject | human | |
dc.subject | mass spectrometry | |
dc.subject | Mediterranean diet | |
dc.subject | metabolic syndrome X | |
dc.subject | metabolome | |
dc.subject | metabolomics | |
dc.subject | randomized controlled trial | |
dc.subject | time factor | |
dc.subject | Adult | |
dc.subject | Biomarkers | |
dc.subject | Body Mass Index | |
dc.subject | Body Weight | |
dc.subject | Cholesterol, HDL | |
dc.subject | Cholesterol, LDL | |
dc.subject | Diet, Mediterranean | |
dc.subject | European Continental Ancestry Group | |
dc.subject | Humans | |
dc.subject | Mass Spectrometry | |
dc.subject | Metabolic Syndrome X | |
dc.subject | Metabolome | |
dc.subject | Metabolomics | |
dc.subject | Time Factors | |
dc.subject | Triglycerides | |
dc.title | Effects of short- and long-term Mediterranean-based dietary treatment on plasma LC-QTOF/MS metabolic profiling of subjects with metabolic syndrome features: The Metabolic Syndrome Reduction in Navarra (RESMENA) randomized controlled trial | |
dc.type | Article |